Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liver Resection Versus Transarterial Chemoembolization for Intermediate-stage Hepatocellular Carcinoma
NCT02755311Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2014
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Phase 3, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall survival at 1 year. Status: unknown.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02755311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02755311.